N/A N=40 Randomized Treatment

A Controlled Study of Uric Acid on the Progression of IgA Nephropathy

IgA Nephropathy

Bottom Line

View on ClinicalTrials.gov: NCT00793585 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2011

Primary outcome: Primary: Change in Renal Function as Measured With eGFR — 68.9; 73.2 eGFR(min/ml)

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: allopurinol (Drug); continue their usual therapy (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Sun Yat-sen University
Primary completion: Jun 2009

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Renal Function as Measured With eGFR	68.9; 73.2	—
SECONDARY The Longitudinal Change in Proteinuria and Blood Pressure(Including Changes in Antihypertensive Drugs Dosing).	1170.4; 1219.3	—

Summary

This prospective, randomized controlled study will evaluate the effect of uric acid on the progression of IgA nephropathy.

Eligibility Criteria

Inclusion Criteria

Subjects of either sex, more than 18 years old, the range of age is 18 to 70 year old.
Biopsy-proven IgA nephropathy.
Proteinuria between 0.15g/d and 3.0g/d; and serum albumin level>3.5g/dl.
Serum creatinine 6 mg//dl (360umol/dl) in female; Uric acid >7mg/dl (420umol/dl ) in male.
No history of taking ACEI or ARB within 2 weeks.
Blood pressure < 180/110 mmHg.
Subjects who agree to participate in the study and sign the informed consent.

Exclusion Criteria

Patients who have received prednisone or immunosuppressive drugs within 2 months.
Patients who must take ACEI or ARB due to other diseases.
Patients who have the history of allergy to allopurinol.
Unwillingness to follow the study protocol.
Active gout within 4 weeks.
Pregnancy or unwillingness to use contraception.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00793585). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.